Search research articles
Contact Us
Filters
Showing results (41-50 of 47) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 47 results.
Protein Expression and Purification
|
November 18, 2005
High levels of protein expression using different mammalian CMV promoters in several cell lines
Wei Xia, Peter Bringmann, John McClary, et al.
Journal of Medicinal Chemistry
|
August 27, 2016
Synthesis and Antiobesity Properties of 6-(4-Chlorophenyl)-3-(4-((3,3-difluoro-1-hydroxycyclobutyl)methoxy)-3-methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one (BMS-814580): A Highly Efficacious Melanin Concentrating Hormone Receptor 1 (MCHR1) Inhibitor
Saleem Ahmad, William N Washburn, Andres S Hernandez, et al.
Journal of Biomolecular Screening
|
April 1, 2005
Differential inhibition of inducible T cell cytokine secretion by potent iron chelators
Stewart Leung, April Holbrook, Beverly King, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 21, 2015
Non-basic azolotriazinone MCHR1 antagonists for the treatment of obesity: An empirical brain-exposures-driven candidate selection for in vivo efficacy studies
Pratik Devasthale, Wei Wang, James Mignone, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 30, 2015
Dihydropyrrolopyrazol-6-one MCHR1 antagonists for the treatment of obesity: Insights on in vivo efficacy from a novel FLIPR assay setup
Pratik Devasthale, Wei Wang, Andres S Hernandez, et al.
Journal of Medicinal Chemistry
|
September 19, 2023
Discovery of <b>12</b> (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders
Wei Meng, Robert Brigance, James Mignone, et al.
Journal of Medicinal Chemistry
|
October 6, 2021
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders
Huji Turdi, Hannguang Chao, Jon J Hangeland, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 47) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 47 results.
Protein Expression and Purification
|
November 18, 2005
High levels of protein expression using different mammalian CMV promoters in several cell lines
Wei Xia, Peter Bringmann, John McClary, et al.
Journal of Medicinal Chemistry
|
August 27, 2016
Synthesis and Antiobesity Properties of 6-(4-Chlorophenyl)-3-(4-((3,3-difluoro-1-hydroxycyclobutyl)methoxy)-3-methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one (BMS-814580): A Highly Efficacious Melanin Concentrating Hormone Receptor 1 (MCHR1) Inhibitor
Saleem Ahmad, William N Washburn, Andres S Hernandez, et al.
Journal of Biomolecular Screening
|
April 1, 2005
Differential inhibition of inducible T cell cytokine secretion by potent iron chelators
Stewart Leung, April Holbrook, Beverly King, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 21, 2015
Non-basic azolotriazinone MCHR1 antagonists for the treatment of obesity: An empirical brain-exposures-driven candidate selection for in vivo efficacy studies
Pratik Devasthale, Wei Wang, James Mignone, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 30, 2015
Dihydropyrrolopyrazol-6-one MCHR1 antagonists for the treatment of obesity: Insights on in vivo efficacy from a novel FLIPR assay setup
Pratik Devasthale, Wei Wang, Andres S Hernandez, et al.
Journal of Medicinal Chemistry
|
September 19, 2023
Discovery of <b>12</b> (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders
Wei Meng, Robert Brigance, James Mignone, et al.
Journal of Medicinal Chemistry
|
October 6, 2021
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders
Huji Turdi, Hannguang Chao, Jon J Hangeland, et al.
Page
of 5